

SARS-CoV-2: Mapping its features that made it as a unique virus

Amro Abd Al Fattah Amara

Protein Research Department, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications, New Borg Al Arab 21934, Alexandria, Egypt; aamara@srtacity.sci.eg

ARTICLE INFO

Received: 15 January 2024
Accepted: 5 March 2024
Available online: 10 April 2024

doi: 10.59400/ephr.v1i1.490

Copyright © 2024 Author(s).

Environment and Public Health Research is published by Academic Publishing Pte. Ltd. This article is licensed under the Creative Commons Attribution License (CC BY 4.0).
<http://creativecommons.org/licenses/by/4.0/>

ABSTRACT: SARS-CoV-2 attracts the attention of nearly the whole world during the last four years. It is a corona virus that responsible for the death of millions. It is responsible for economical corruption in many countries. As a response, excessive vaccination programs were installed everywhere. But many variants are elevated and the virus prove ability to escape from the immune system because of different mutations. The progress in different scientific domains, instrumentation, bioinformatics, and the like, makes fast vaccines developing easier. As a response, new strategies were introduced including new vaccine production and administration strategies, genomic surveillance, immunopeptidome, gene sequencing, and the like, to enable the vaccine to cover all the targeted populations in correct time and to install early alarming system against any elevated new variants. This review contains more information about some important station for the history of vaccine development and the strategies invented by scientists to control different viruses and other microbes. Some important issues that might influence the type of the used vaccines about the SARS-CoV-2 are addressed. They include their symptoms, the virus evasion of the innate immune system, the response of the adaptive immunity, and the like. Although the world still in need of better understand for the SARS-CoV-2 behavior to gain the war against it, previous historical successful vaccine productions, important examples, and station during the human struggle against the viruses are described and discussed.

KEYWORDS: epitopes; control strategies; immunopeptidome; vaccine; variant; SARS-CoV-2

1. Introduction

It is wise to cut the viruses transmission cycle rather than treating it. Wild animals are the most reclaimed ones. Sign about humans' awareness about disease transitions could be traced in our everyday practices, legends, history, and folk memory, different activities, observations, experiences, knowledge, practices, and the like. For example, the criteria used to classify the animal species of concern for SARS-CoV-2 epidemiology was the ability to shed infectious virus and to transmit SARS-CoV-2 to other individuals. Evidence of animals that could transfer SARS-CoV-2 include American mink (*Neogale vison*), raccoon dog (*Nyctereutes procyonoides*), cat (*Felis catus*), Syrian hamster (*Mesocricetus auratus*), ferret (*Mustela furo*), house mouse (*Mus musculus*, for some virus variants only), Egyptian fruit bat (*Rousettus aegyptiacus*), deer mouse species (*Peromyscus spp.*, not present in Europe) and white-tailed deer (*Odocoileus virginianus*)^[1]. Keeping away from wild animals will help in cut the cycle of unusual viruses like those who start to attack humans in the last decades. Unusual viruses could also be transmitted from wild animals to domesticated

ones. Historically, wild beasts were domesticated (such as cats and dogs) to protect against other wild ones (such as rats, foxes, wolves). During their everyday computation/activities, dangerous microbes start to come to our backyard. To avoid such mix, some beliefs and practices of some ethnic groups describe orders include inhabiting eat of any kind of meat! Other inhabited eating carnivores or beasts, which have nails. It is not clear yet why wild beasts transfer dangerous diseases but domesticated ones did not; but only after sudden attack or contact with wild animals. That might be because of long historical adaptation and contacts between human and domestic animals. Meanwhile in current years, this stability was proved to be a fable. Farmers and companies active in the business of animals farming should put in their account animals' protection against any contact with the wild animals as one major safety concern.

Farm animals usually did not transfer serious illness, even viruses such as smallpox (cows), sheep pox (sheep), chicken (chickenpox), are not fatal to us. In contrast, they could protect us against our own specific viruses, such as the seriously fatal virus, the smallpox. Apparently, lay people have a concise correct image about this perception (such as the story of the milkmaid and Edward Jenner). Our modern lifestyle kept us away from the domesticated animals, and near to some wild animals (such as the zoo). Did we miss those free chances for protection? Be nearer to the wild animals? And the like.

One important activates is the nonpharmaceutical interventions for managing SARS-CoV-2. Such activities include face masks, hand hygiene, respiratory etiquette, surface and object cleaning, ventilation, UV light, humidity, contact tracing and quarantine, rapid antigen testing, school closures, travel-related measures, stay at home, and the like^[2]. Meanwhile, the viruses are usually able to bypass the first defense line which keeps them away from us with correct natural distances. For that, during our historical straggles against pathogens including viruses, the human talent invents some amazing protection strategies such as the variolation (more details blow), herbal treatment, patients' isolation, and the like. But, in some cases the community becomes susceptible. Epidemic strike is an example. But epidemic usually happened after a large rest period, which did not mean that the virus did not infect at all. But infect in levels less than the epidemic level. That is a sign of the presence of either herd immunity or other specific conditions that enable the viruses and other pathogens to attack us in levels could be given the name "sub-Epidemic".

How communities interact with illness? Particularly after the epidemic is disappeared! Measles could be given as an example. The old art starts when a child (gain infection) has symptoms like measles. His mother telling other mothers and they all are gathering their children (those not gain measles before) in one place to gain the infection and address them red clothes. Science proves that measles virus (and some other viruses) could be more fatal for adults; but not for the children! Sometime strong immune systems like the adults' immune system could cause serious side effect such as cytokine storm in case of SARS-CoV-1 and in particular cases with some variants of SARS-CoV-2 or for patients with health problems. Should we follow this concept? Did our chilled (non-vaccinated) become immunized as well by using such simple practice? Today, the image is completely different and many did not like to experience such successful old practices. Nerveless, scientists are invited to reinvestigate any of them and re-modulate them to be more acceptable to the modern communities. Anyhow, such practices still running here and there and did not completely disappear. Keeping any previous successful experiences running and stopping pushing a force to replace them with modern technology might be useful in critical cases or places where there is no possibility to use modern technology (e.g., vaccines) or there is not enough capacity to use modern technology for everyone.

The two famous historical pandemic viruses are smallpox that infects the Native American (unknown death number) and the Spanish influenza (50 million deaths in 1918). The Greek historian Herodotus born 484 BC documented that every Babylonian was an amateur physician, since it was custom to lay sick in the street, so that, anyone passing by might offer advice^[3,4]. Thucydides (430 BC) describe plague in Athens (over 100,000 deaths in 430 BC); “only those who had recovered from the plague could nurse the sick because they could not contract the disease a second time^[5]. In the past, pandemic areas are isolated. No one enters it. Few know that one should also not leave his place to another. Other famous documented events include *Yersinia pestis* (50 million deaths in 1340). Human was always searching for information, tools, ideas, advice, and the like, that could help him particularly to enable him to be healthy to be able to satisfy the different other life demands.

Earlier time to specifying viruses using a microscope, philosopher, and thinkers such as Pasteur’s emphasis that virulence is not a constant attribute but a variable property. A property that can be lost and later recovered. Virulence could be decreased, but Pasteur suspected that it could be risen as well. He believed that risen virulence was what gave rise to epidemics^[6]. Successfully, smallpox and rinderpest were nearly eradicated and many of the human viruses become under control. Meanwhile, in the last decade’s conversion was happened. Other viruses start to attack us with new infections caused by novel uncommon virus species. For examples, HIV (40 million deaths in 1980–2000), H1N1 “Swine flu” (300,000 deaths in 2009), Zika, Ebola, Severe Acute Respiratory Syndrome (SARS), Middle East respiratory syndrome (MERS)” and SARS-CoV-2 “COVID-19”. Did we change our lifestyle? Which factor(s)/activity could be claimed? This review concern with collecting some evidence and highlighting some odd responses (such as immunocompromised patients, children, precedents, patients with SNP in particular gene(s), and the like.)

One should not neglect effort made by scientific institutions, companies, organizations (such as the World Health Organization (WHO)/FAO), political and decision makers, and the like to establish a global safe system to control the existing pandemic(s)/epidemic(s) or prevent expected coming ones. Also, the community fast responses to instruction given by experts have a good impact on controlling some issues. Nerveless, the lifestyle, economic activities, and social behaviors of our world are still being stuck by this pandemic^[7].

The world reaches some acceptable level of collaboration. Meanwhile, today the warning from a newly elevated infection in different places in the world still alarming. The world should install a better strategy for prevention, protection, and treatment. And questions should be always found correct attention. For example, why viruses attack and re-attack us? And what could we do?

This review deal with

- 1) Mapping critical stations in human history concerning the viruses, immunity and vaccine development and production.
- 2) Giving the essential information about the SARS-CoV-2 virus, symptoms, the immune system reactions, the different personal responses, the important molecular aspects, and the like.
- 3) Summarizing different tactics, strategies, and how scientists found solutions might help many and even might open a new window for controlling SARS-CoV-2 and the other viruses. An idea which might not be useful for one or in a certain place might be useful for others where they might be still need time to be compatible with the standard codes.
- 4) Describing different vaccines -prepared by different strategies- including old (viable, attenuated, inactivated, antibodies, and the like) new (RNA, DNA, protein, peptide vaccines...).

- 5) Describing important strategies (immuno-peptidome, personalized treatment, virus ghost...), that could help in controlling viruses in general and SARS-CoV-2 as the hottest issue. One could not forget that a simple strategy save some countries from the antibiotic resistance to the antibiotic, which simply by keeping some antibiotic out of the pharmacy and enable their use only in the hospitals (in emergence cases). Other ideas or concepts might be extracted from nonspecific similar experiences as well.

2. Corona virus

There are two genera in Coronaviridae family: Coronavirus and Torovirus. Coronaviruses are enveloped, 120–160 nm particles, with unsegmented genome of a positive-sense single-stranded RNA (infectious) (26–e32 kb)^[8]. The helical nucleocapsid is 9–11 nm in diameter. SARS-CoV-2 can largely be transmitted through contact, particle transition, airborne, fecal-oral, blood-borne, mother-to-infant, animal-to-animals, and animal-to-human (Hossain et al. 2020). The virus enters the human body through mucosa of the nose and oropharynx, and some get deposited in lungs. Beside the lungs, other organs expressing angiotensin-converting enzyme 2 (ACE2) receptors on the surface of cells such as heart, kidneys, and intestines^[9,10]. The viral genome (29.8 kp) consists of 14 open reading frames (ORFs) which encode 27 proteins. Two thirds of viral RNA is translated into two large polyproteins. In SARS-CoV and MERS-CoV, two polyproteins, pp1a and pp1ab, are processed into 16 nonstructural proteins (nspl-nspl6), which form viral replica transcriptase complex. Those nsps rearrange membranes originating from rough endoplasmic reticulum (RER) into double-membrane vesicles where viral replication and transcription occur^[11,12]. The other ORFs of SARS-CoV-2 on one third of the genome encode four principal structural proteins: Spike (S), envelope (E), nucleocapsid (N) and membrane (M) proteins, also several accessory proteins with unknown functions which do not participate in viral replication.

2.1. The status of the current pandemic, SARS-CoV-2

The SARS-CoV-2 emergence in 2019 is causing ongoing COVID-19 pandemic. For example, On 31 August 2022, >600 million COVID-19 patients, and 6.5 million deaths were reported globally^[13,14].

2.2. Evasion strategies

Coronaviruses (CoVs) have advanced evasion strategies to bypass host defense, and increase replication, and transmission^[15–19]. SARS-CoV-2 can evade the first innate immune responses. This could be happened by dropping IFN levels. Patients are genetically and healthy different. With mild, and moderate COVID-19 patients have in their serum low levels of IFNs types I and III^[17,19]. The IFN type I, and III production are reduced at the post-transcriptional levels. SARS-CoV-2 inhibits the release of mRNA from transcription sites, and/or triggers degrading transcripts in the nucleus^[17,19]. SARS-CoV-2 also encodes additional proteins that disrupt RLR sensing pathways, signaling, or effector functions. SARS-CoV-2 ORF9b, N and M proteins can inhibit the expression of IFN- β , and proinflammatory cytokines. It does that by interfering with RIG-I, and MDA5 pathways. ORF9b also capable of blocks TLR3–TRIF pathway^[16,19–22]. Moreover, SARS-CoV-2 nonstructural proteins also contribute to host immune evasion^[13]. There are other mechanisms involved in evasion of the innate immune system such as mutating the target site(s).

2.3. SARS-CoV-2 entry

Entry receptors

COVID-19 can affect almost any organ^[23–26]. The virus protein S is a fusion glycoprotein. It divided

into two functionally distinct parts (S1 and S2)^[27–29]. SARS-CoV-2 can bind to endothelial layer through angiotensin-converting enzyme 2 (ACE 2) receptors expressed on target cells. The S protein is responsible for receptor-binding and determines host range and cell tropism^[11]. The S proteins of various coronaviruses interact with a wide range of receptors including ACE2, dipeptidyl peptidase 4, aminopeptidase-N, and sialic acid moieties to facilitate the entry process. This diversity of receptor use may help explain strong potential for zoonotic transmission of coronaviruses to humans^[30]. SARS-CoV-2, like SARS-CoV, use angiotensin-converting enzyme 2 (ACE2) as a receptor to enter cells, with its main co-receptor transmembrane protease serine 2 (TMPRSS2)^[9,10,31–42]. This large protein comprises a short C-terminal tail located inside virion, a transmembrane domain, a rod-like S2 domain responsible for the fusion process, and a large globular S1 domain, within which RBD is located. In advance of interaction with entry receptors, virus binds to adhesion receptors. This concentrates virus on the cell surface. Next, virus binds to entry receptors, which initiates a fusion of viral and cellular membranes. Finally, viral nucleoprotein enters cytoplasm. The internalization site depends on the availability of proteases need to trigger a transformation of S protein into fusogenic state. *In vitro* models show that human coronaviruses use an endocytic entry pathway in which gradual acidification of microenvironment activates endosomal cathepsin B (catB) and cathepsin L (catL), which effectively prime S protein and begin entries^[43,44]. Other studies showed that human coronaviruses bypass this process and use serine proteases (transmembrane protease serine 2 [TMPRSS2], kallikrein 13) present on the cell surface. In such cases, fusion occurs on the cell surface and endocytosis is not need^[9,42,45–50].

Furin (cleaving SARS-CoV-2 spike protein) and CD147 (basigin) have arisen as possible viral entry facilitators^[41,51–55]. Three C-type lectin receptors, CD169 (Siglec-1, Sialoadhesin), CD209 (DC-SIGN) and CD299 [LSIGN, DC-SIGNR, C-type lectin domain family four-member M (CLEC4M)], enhance ACE2-dependent viral entry in their role as attachment receptors^[56–60]. CD169 is a surface molecule expressed in macrophages of several anatomical sites that mainly promote adhesion to neutrophils, and was described as an entry mediator for retroviruses^[61]. CD209 was proposed to act as a receptor on liver sinusoidal endothelial cells^[62]. Lectin proteins were shown to activate the complement system^[63] and stir further inflammatory response by beginning cytokine production in myeloid cells^[64], which fits well into established the concept of inflammasome activation by SARS-CoV-2^[65]. Neuropilin-1 (NRP-1), originally described as a pro-angiogenic protein and a mediator for neuronal cell guidance in developing nervous system^[66], was shown to potentiate viral transmission of SARS-CoV-2^[38,39,67]. Kringle containing transmembrane protein 1 (KREMEN1) and asialo-glycoprotein receptor 1 (ASGR1) as ‘receptor-like host factors’ in SARS-CoV-2 were proposed^[68,69]. Both proteins are described acting independently from ACE2. Although KREMEN1 is a known entry receptor for several enteroviruses, such as coxsackievirus A10^[70,71]. Alternative viral entry molecules, monocytes and (alveolar) macrophages were described as possible vector cells for SARS-CoV-2 entries and transmission^[72–77]. Viral replication in AMs also viral uptake was shown in mouse models and using transcriptomic profiling^[72,76]. A cellular shift towards proinflammatory monocytes was described in alveoli^[78]. SARS-CoV-2 uses M1 macrophages with its distinct proinflammatory cytokine profile as a vehicle for transmission and infection of alveolar epithelium^[72,79]. Ingesting of SARS-CoV-2 in monocytes elicits a strong inflammatory response^[80,81], which is critical in COVID-19. Bräutigam et al.^[82] discussed role of 10 possible viral entry molecules, ACE2, TMPRSS2, furin, CD147, CD169, CD209, CD299, NRP-1, ASGR1 and KREMEN1 and address their clinical relevance and anatomical distribution^[82]. Bräutigam et al.^[83] show that SARS-CoV-2 N-protein is detectable in AMs expressing ACE2 and other entry receptors and suggested an important role for AMs as a cellular hub for entry and transmission of SARS-CoV-2^[83]. Although the lungs are the SARS-CoV-2 target organ, 2% of cells in this tissue is ACE2 positive. Nevertheless, ACE2-positive cells are

extensively found in the small intestine, gallbladder, kidneys, testes, thyroid, adipose tissue, heart muscle, vagina, breast, ovary, and pancreas^[9,24,25,27,84,85].

3. Symptoms of COVID-19

The symptoms of COVID-19 could be used as a pro-fast diagnostic tool. They are variable ranging from mild symptoms to fatal illness. Meanwhile, they can be categorized to three common groups of symptoms were identified.

- Group 1 where patients developed a cough, sputum, shortness of breath, and fever.
- Group 2 where patients developed a musculoskeletal symptom cluster with muscle and joint pain, headaches, and fatigue.
- Group 3 where patients developed a cluster of digestive symptoms with abdominal pain, vomiting, and diarrhea.

Common symptoms include coughing, fever, loss of smell (anosmia), taste (ageusia), headaches, nasal congestion and runny nose, muscle pain, sore throat, diarrhea, eye irritation, and toes swelling or turning purple. In moderate to severe cases, they cause breathing difficulties. At least a third of people who are infected with the virus do not develop noticeable symptoms at any point in time^[86,87]. The same strains show less severity. For example, an Omicron variant in the U.S. since December 2021 has less severe symptoms compared with other variants^[88]. Meanwhile, SARS-CoV-2 dissimilar variants with diverse severity were identified.

4. SARS-CoV-2 variants

Mutations at N-terminus and receptor-binding region, including p.Glu484Lys are found in most dangerous variants^[89]. Dissimilar variants include the UK, South Africa, India, California and Brazilian, have appeared. Delta variant is more virulent and speedily spread^[90]. The variants of concern (VOC) include Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529). Meanwhile Delta and Omicron being most alarming ones^[89]. In 2022, a new variant with Delta backbone and Omicron spike has arisen^[91]. The SARS-CoV-2 virus is highly mutated^[92]. Omicron itself has >100 subvariants at present, among which BA.1 (21K), BA.2 (21L), BA.4 (22A), BA.5 (22B), and BA.2.12.1 (22C) are dominant ones^[93]. The Omicron variant has a high risk of immune evasion^[94,95]. The multiple mutations encompassing epsilon variant demonstrate the independent convergent changes in SARS-CoV-2, with its spike protein mutation L452R in Delta (L452R), kappa (L452R), and Lambda (L452Q) is present^[96]. To control such un-normal circumstances, administering a third booster dose is motivated after emergence of B.1.617.2 (delta) variant throughout the world. Third doses of vaccines mRNA1273, BNT162b2, AZD1222 and Coronavac prompted a spike in levels of neutralizing antibodies, when administered several months after the second dose. These decrease in vaccine-induced antibody levels reflect a decline in protection against the virus^[97].

5. SARS-CoV-2 during the infection process

SARS-CoV-2 affects different important organs, but the most important one is the lung. A few minutes without oxygen can result in death or brain deterioration^[98]. SARS-CoV-2 could show no symptoms till it becomes well adapted in infected person's cells. For that, asymptomatic individuals speedily spread the virus^[90,99,100].

Some other properties involved in its pathogenicity could be summarized in the following points:

- 1) Its entry and replication mode in cells during the infection/cell defense mechanism causes severe reaction.
- 2) In lungs their various activities as well as the activity of the immune system (both of cellular and humeral immune responses) and any existed co-infection interferes with the respiration process. SARS-CoV-2 replication in airway epithelia needs motile cilia and microvillar reprogramming^[101].
- 3) The fast virus promoters utilize the energy and the power of the lung cells, because of the virus fast replications.
- 4) The time between correct response of the adaptive immune system and its adaptation of lung cells is enough to put the immune system against a fact that virus is already invading the cells.
- 5) Innate pathways are diss-regulated in some individuals during SARS-CoV-2 infection.
- 6) Various related cell death pathways, including robust NETosis or PANoptosis.
- 7) T cells are also affected by SARS-CoV-2 infection.

5.1. Cytokine storms and ROS

Some viruses cause a localized, exaggerated response, resulting in secreting high levels of cytokines. There is some evidence that SARS epidemic of 1993 may have caused a similar, unregulated, immune cell cytokine secretion^[102].

Sars-CoV-2 as being a new virus, did not experience before by our immune system, it will be capable of bypass innate defenses and reach to lung cells even to the immune cells. Our first defiance lines the innate immune, it includes type I, type II and type III interferon signaling cascades and interferon-induced genes. They are playing a role in limiting viral entry, translation, replication, and assembly, and accelerate developing adaptive immunity by providing co-stimulatory signals and upregulating expression of important proteins (for example, MHC antigens). While few specific interferon-stimulated genes (ISGs) were documented to have direct antiviral activity against SARS-CoV-2, some were described, including ISG15, which augments MDA5 signaling after recognizing SARS-CoV-2 viral RNA^[103], and LY6E, which appears to block fusion and entry of coronaviruses into cells. Larger-scale genetic screens evaluated the effect of human ISGs on SARS-CoV-2 replication^[104].

Excessive innate immune activation could lead to systemic inflammation and severe disease. Thus, a balance must be achieved that speedily restricts SARS-CoV-2 infection without resulting in excessive inflammation and tissue injury. NK (natural killer) cells have antiviral activity against SARS-CoV-2 but become functionally impaired in severe COVID-19^[105].

The variable innate immune response of healthy people can be genetically confirmed with the TLR receptor. Sepsis patients with SNPs of TLR1 hypermorphic variants have an association with a risen susceptibility to organ dysfunction, death, and gram-positive bacteremia infection^[106]. TLR4 is the major receptor for lipopolysaccharide (LPS). Variants of TLR4 can make individuals susceptible to sepsis. Genome-wide association studies (GWAS) have linked TLR4 polymorphisms to pathogen susceptibility and disease severity^[107]. Plasma cytokines should be monitored dynamically to assess the degree of cytokine storm. SARS-CoV-2 might induce excessive and prolonged cytokine responses, resulting in lung damage and multiple organ failure (MOF). A violent cytokine storm causing immune pathological damage may be a real “killer” in critically ill patients.

Pathogenic mechanism of inflammatory cytokines, derived from IMM and neutrophils^[108]. Therapeutic approaches to manage COVID-19 cytokine storm decrease the COVID-19 associated morbidity and mortality^[109]. SARS-CoV-2 spike induces autophagy through intracellular ROS-suppressed PI3K/AKT/mTOR axis, which then leads to inflammatory responses and apoptosis in infected cells.

Anti-inflammatory drugs are not effective (remain unclear)^[110]. It is difficult to illuminate separate roles of pyroptosis in COVID-19, which include inflammasomes and caspases^[111]. Managing its pathogenesis through specific cytokine storm checkpoints can reduce mortality^[112]. The cytokines produced from COVID-19 infections have also contributed to the elevation in the number of T-cells in asthmatic patients^[113].

5.2. Bacterial-SARS-CoV-2 associated-co-infections

Identifying and treating other respiratory pathogens is important^[114]. Bacterial co-infections play additional pathogenic roles^[115]. Diverse individuals have diverse bacterial co-infection^[116]. Co-infecting pathogens are important in any treatment strategies^[117,118]. SARS-CoV-2 infection is associated with a distinct shift in compositing the nasal microbiome, including *P. aeruginosa* and *B. cepacia*^[119]. *P. aeruginosa* is capable of produce alginate and express T6SS gene^[120].

5.3. Viral co-infection

Fage et al.^[121] highlighted that SARS-CoV-2 existing with other viruses (that infect the respiratory organ) could help in its control^[121]. Influenza a(h1n1)pdm09 virus but not respiratory syncytial virus could interfere with SARS-CoV-2 replication during sequential infections in human nasal epithelial cells. According to Fage et al.^[121] the mechanism involved in the viral interference is mediated by producing interferon^[121].

5.4. Cell death during the infection

Proteases play important roles in SARS-CoV-2 infection and replication. Various cell death pathways, including robust NETosis or PANoptosis. Parallel inhibition of NLRP3 assembly along with gasdermin D oligomerization increases the therapeutic effect of caspase-1 inhibition to prevent pyroptosis^[122]. Necrosis, including necroptosis and pyroptosis, is the predominant form of alveolar epithelial cell death in COVID-19-induced. The DAMPs released from necrotic alveolar epithelial cells are potential drivers of progressive alveolar tissue damage in COVID-19^[123]. The related neuronal damage in the URT leading to anosmia^[111,119]. β -Coronaviruses can be hypothesized that cell death pathways are maintained. The role of ORF3a in inducing the extrinsic pathway similarly to SARS-CoV infection should be deepened. T cells are also affected by SARS-CoV-2 infection. SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation^[124]. Molecules such as c-FLIP or NF- κ B inhibitors or caspase-8 activators could be included among the drugs used to contrast COVID-19. Fast and direct approaches to target the uncontrolled response of the immune system after the infection could be using molecules to inhibit the action of TNF and IFN- γ . SARS-CoV-2 infection triggers several cell death pathways that could become pharmacological targets^[125].

Age, gender and personal immunity

Personal genetic play a role in determining susceptibility to COVID-19. Patients are not uniformly responded to complement-targeting therapies. SNPs (single nucleotide polymorphisms) in complement and coagulation pathways underlie the genetic predisposition towards severe COVID-19 disease in some patients. Interferons or other immune mediators can drive differential susceptibility^[126–128]. Patients with autoantibodies account for up to 10% of hospitalizations for severe COVID-19 count 20% of deaths^[129,130]. Anti-interferon antibodies are present in a small fraction of the critically ill patients, especially found in men.

Age, male gender and some pre-existing conditions, such as severe asthma, are associated with worse COVID-19 outcomes, including death. Gender and age responsible for changes in myeloid cell

populations which are a feature of severe COVID-19^[131]. Higher myeloid-derived suppressor cells (MDSC) count in patients with COVID-19 correlate with reduced transcription of cytokines by peripheral monocytes^[132]. Defective DC migration to the lymph nodes and the reduced priming of T cells in older mice is reported because of their risen expression of prostaglandin D2 (PGD2). A PGD2 antagonist protected older mice from disease^[133]. MS1' cells are risen in patients with severe COVID-19. These cells are thought to be immunosuppressive and may contribute to the reduction in T cell populations that was seen in severe COVID-19. Cystic fibrosis (CF) patients with poorer lung function and post-transplant status are at higher risk for worse clinical outcomes in coronavirus disease^[134].

Elderly with weak immune systems and persons with autoimmune were the most vulnerable to contract the virus^[116,135]. Gender and age can be associated with specific uncontrolled inflammatory immune responses, which drive aggressive inflammation, hyper-cytokemia, and because of the wide organotropism of SARS-CoV-2 collateral tissue damage and systemic failure^[136,137]. That could be related to imbalanced ACE/ANGII/AT1R and ACE2/ANG(1-7)/MASR axes signaling^[138].

6. Global SARS-CoV-2 genomic surveillance

Because of the elevation of new variants after excessive vaccination programs, it becomes clear that there is a need for installing a system that can monitor any new elevated variant to be identified on the spot. That enables better control and better distribution for the data that could enable fast production of new vaccine specific to this variant. For example, Saifi et al. (2022)^[139] have conducted a study on SARS-CoV-2 VOCs, mutational diversity, and clinical outcomes^[139]. They find significant mutations, T4685A, N4992N, and G5063S in the RdRp; T19R in the NTD spike; and K444N and N532H in the RBD spike region to be associated with the Delta mortality patients. Mutations, T19I in the NTD Spike, Q493R and N440K in the RBD spike, G18C, and R413S in the Nucleocapsid gene to be significantly associated with the Omicron mortality patients. The docking studies of Remdesivir with mutant viral proteins including Nsp12, Nsp13, and Spike RBD region demonstrated a reduction in the binding strength of Remdesivir to mutant Spike proteins for both the mortality groups. Their findings suggested the possible role of these mutations in reduced drug efficacy and a possible role in the progression of disease severity^[139]. Emerging SARS-CoV-2 VOCs causes an Impending Global Crisis^[140].

In fact, none of the new vaccine production strategies which based on the virus genome and structure/function will be worked without the virus genome sequence. Meanwhile, the first SARS-CoV-2 genomes were shared on 10 January 2020^[24,25,141]. United Kingdom established the COVID-19 Genomics UK Consortium (COG-UK). U.S. government invested US\$1.7 billion to expand genomics capacity for COVID-19^[141,142]. In Australia, integrated public health genomics surveillance system is developed (AusTrakka)^[143]. Another genomic surveillance was built up by South Africa^[141,144]. Puerto Rico install its own^[145]. In Italia over 20,000 viral genomes since the starting of the pandemic are sequenced^[146].

This permitted:

- 1) Identify new viral variants^[146].
- 2) Detecting circulating viral diversity.
- 3) Identifying epidemiologically linked individuals.
- 4) Identifying national and international transmission routes.
- 5) Enables bioinformatics and knowledge resources detecting emerging VOC prior to their international expansion.
- 6) Large-scale models with relatively sparse sampling were used^[141,147,148].

CDC summarizes the importance of a comprehensive system for SARS-CoV-2 genetic surveillance is important in three points^[149]:

- 1) Mutations (nucleotide substitutions) occur in viruses and accumulate with continued viral spread; these mutations result in variants that may have dissimilar attributes. Genomic surveillance identifies circulating variants to speedily inform public health response efforts^[149].
- 2) Testing, treatment, and vaccination programs can be improved based on regularly updated surveillance of variants, including updating forthcoming vaccines if needed^[149].
- 3) Detecting variants that are more transmissible or cause more severe disease support outbreak preparedness, prevention efforts, and strengthens public health response^[149].

Several other studies report the importance of the genomic analysis in controlling the epidemic SARS-CoV-2^[150]. Integrated genomic surveillance enables tracing of person-to-person SARS-CoV-2 transmission chains^[151]. For genomic surveillance of SARS-CoV-2, ECDC recommends two complementary sampling approaches^[152]:

- Representative sampling of SARS-CoV-2 RT-PCR positive cases from existing, population-based surveillance systems^[152];
- Targeted sampling of SARS-CoV-2 positive cases occurring in special settings or populations^[152].

Bhat et al. (2021)^[153] reported that VOCs and VOIs provide a framework for closely monitoring the low-frequency mutations for their forthcoming functional importance in transmission and immune escape^[153]. These methods offer novel means to detect variants that are phenotypically or antigenically diverse^[154]. Genomic surveillance will facilitate greater early anticipation^[154]. Improved SARS-CoV-2 sequencing surveillance permits identifying new variants and signatures in infected patients^[147]. SARS-CoV-2 shows a complicated relationship among virus antigenicity, transmission and virulence^[155]. Predicting and cataloging VOC prior their arise would enable the preemptive design of therapeutics and public health measures to be employed at need^[156].

7. Immunoepitidome

The epitope profiling in RBD-Based antigens of SARS-CoV-2 revealed the critical antigenic determinants. It includes three immunodominant epitopes. They are a conserved epitope (350VYAWN354) exposed on the surface of the viral spike protein trimer; a variable epitope among diverse virus strains (473YQAGSTP479) found in the receptor-binding motif (RBM) and a conserved cryptic cross-reactive epitope (407VRQIAP412) shared by RBD of SARS-CoV-2, and SARS-CoV^[157].

These data can elucidate humoral immune responses to the spike protein's RBD. That will enable developing new vaccines^[158]. SARS-CoV-2 mutated epitopes can erode the adaptive immunity. Identified epitopes in the COVID-19 mRNA vaccine are important. They can be used as a basis for study the immune escape, viral variants, and the design of the vaccine, and therapy. Mutation panel assays for VOCs' epitopes induced by the mRNA vaccine is rich in breadth. VOC can grant resistance against viral evolutionary escapes of the future. That represents an advantage of vaccine-induced immunity^[158]. Human leukocytes' antigens class I Epitopes (HLA-I) and class II (HLA-II) were identified. They were used for immunoepitidomes. Epitopes mostly are canonical and out-of-frame peptides derived from spike and nucleocapsid proteins. The epitopes of the membrane proteins come in the second level^[159].

In cito antigens are proteolytically processed into peptides. The peptides then presented on the surface of infected cells by human MHC. MHC known as HLA molecules presented the peptides to T^[160]. This peptidome of HLA represents an immunological signature. The circulating cytotoxic T cells (CD4⁺

and CD8⁺ T cells) can recognize it through their T cell receptor (TCR). Its cause clearance and lysis to infected cells and catalyzing immune responses^[161]. Different indigenous populations express distinctive and unique HLA profiles. That varies from other ethnic groups' profiles^[162]. Exploring the SARS-CoV-2-derived HLA peptide repertoire enables characterizing the viral epitopes. These specific epitopes can activate cytotoxic T cells. B cells recognize external viral epitopes. T cells can be elicited by all viral proteins. That includes several canonical and non-canonical viral ORFs^[20]. Bioinformatics prediction for the binding affinity of HLA-I and HLA-II was employed to detect the epitopes of SARS-CoV-2^[163–169]. The data are based on the reactivity assays and biochemical binding assays (IMMUNITRACK)^[164,167,169–171].

Acknowledgments

The author would like to thank the referees for their invaluable comments and suggestions which led to the improvement of the manuscript.

Conflict of interest

The author declares no conflict of interest.

Abbreviations

CF	cystic fibrosis
GWAS	genome-wide association studies
HDCV	human diploid cell vaccine
SG	interferon-stimulated genes
MDSC	myeloid-derived suppressor cells
MERS	Middle East respiratory syndrome
MOF	multiple organ failure
MV	measles virus
MVA	modified vaccinia Ankara
NDV	Newcastle disease virus
NK	Natural killer
ORF	Open reading frames
PBMC	Peripheral blood mononuclear cells
PCEC	purified chick embryo cell culture
PVRV	purified vero cell rabies vaccine
RBD	receptor-binding domain
RBM	receptor-binding motif
RER	rough endoplasmic reticulum
SARS	severe acute respiratory syndrome
SNP	single nucleotide polymorphisms
TCR	T cell receptor
VOC	variants of concern
VSV	vesicular stomatitis virus
WHO	World Health Organization

References

1. Nielsen SS, Alvarez J, Bicout DJ, et al. SARS-CoV-2 in animals: susceptibility of animal species, risk for animal and public health, monitoring, prevention and control. *EFSA Journal*. 2023; 21(2).
2. Murphy C, Wong JY, Cowling BJ. Nonpharmaceutical interventions for managing SARS-CoV-2. *Current Opinion in Pulmonary Medicine*. 2023; 29(3): 184-190. doi: 10.1097/mcp.0000000000000949
3. Rossi M. Homer and Herodotus to Egyptian medicine. *Vesalius*; 2010.
4. Thomas R. Greek medicine and Babylonian wisdom: circulation of knowledge and channels of transmission in the archaic and classical periods. *Stud Anc Med*. 2004; 27: 175-185.
5. Kraut BH. Medicine and the arts. Histories: [excerpt] by Thucydides. Commentary. *Academic Medicine*. 2010; 85(6): 1008. doi: 10.1097/acm.0b013e3181dc67d4
6. Encyclopædia-Britannica. Pasteur, Louis: Encyclopædia Britannica Student and Home Edition. Encyclopædia Britannica; 2013.
7. de Wit E, van Doremalen N, Falzarano D, et al. SARS and MERS: recent insights into emerging coronaviruses. *Nature Reviews Microbiology*. 2016; 14(8): 523-534. doi: 10.1038/nrmicro.2016.81
8. Su S, Wong G, Shi W, et al. Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. *Trends in Microbiology*. 2016; 24(6): 490-502. doi: 10.1016/j.tim.2016.03.003
9. Sadhukhan P, Ugurlu MT, Hoque MO. Effect of COVID-19 on Lungs: Focusing on Prospective Malignant Phenotypes. *Cancers*. 2020; 12(12): 3822. doi: 10.3390/cancers12123822
10. Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature*. 2003; 426(6965): 450-454. doi: 10.1038/nature02145
11. Masters PS. The Molecular Biology of Coronaviruses. *Advances in Virus Research*. 2006; 193-292.
12. Knoops K, Kikkert M, Worm SHE van den, et al. SARS-Coronavirus Replication Is Supported by a Reticulovesicular Network of Modified Endoplasmic Reticulum. *PLoS Biology*. 2008; 6(9): e226. doi: 10.1371/journal.pbio.0060226
13. Low ZY, Zabidi NZ, Yip AJW, et al. SARS-CoV-2 Non-Structural Proteins and Their Roles in Host Immune Evasion. *Viruses*. 2022; 14(9): 1991. doi: 10.3390/v14091991
14. WHO. WHO Coronavirus (COVID-19) Dashboard. Available online: <https://covid19.who.int/> (accessed on 2 January 2024).
15. Konno Y, Kimura I, Uriu K, et al. SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant. *Cell Reports*. 2020; 32(12): 108185. doi: 10.1016/j.celrep.2020.108185
16. Li JY, Liao CH, Wang Q, et al. The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway. *Virus Research*. 2020; 286: 198074. doi: 10.1016/j.virusres.2020.198074
17. Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. *Cell*. 2020; 181(5): 1036-1045.e9. doi: 10.1016/j.cell.2020.04.026
18. Burke JM, St Clair LA, Perera R, et al. SARS-CoV-2 infection triggers widespread host mRNA decay leading to an mRNA export block. *RNA*. 2021; 27(11): 1318-1329. doi: 10.1261/rna.078923.121
19. Diamond MS, Kanneganti TD. Innate immunity: the first line of defense against SARS-CoV-2. *Nature Immunology*. 2022; 23(2): 165-176. doi: 10.1038/s41590-021-01091-0
20. Weingarten-Gabbay S, Klaeger S, Sarkizova S, et al. SARS-CoV-2 infected cells present HLA-I peptides from canonical and out-of-frame ORFs. Cold Spring Harbor Laboratory; 2020.
21. Ebinger JE, Fert-Bober J, Printsev I, et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. *Nature Medicine*. 2021; 27(6): 981-984. doi: 10.1038/s41591-021-01325-6
22. Sui L, Zhao Y, Wang W, et al. SARS-CoV-2 Membrane Protein Inhibits Type I Interferon Production Through Ubiquitin-Mediated Degradation of TBK1. *Frontiers in Immunology*. 2021; 12. doi: 10.3389/fimmu.2021.662989
23. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. *The Lancet*. 2020; 395(10223): 507-513.
24. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *New England Journal of Medicine*. 2020; 382(8): 727-733. doi: 10.1056/nejmoa2001017
25. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*. 2020; 579(7798): 270-273. doi: 10.1038/s41586-020-2012-7
26. Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China. *JAMA*. 2020; 323(13): 1239. doi: 10.1001/jama.2020.2648
27. Kantarcioglu B, Iqbal O, Lewis J, et al. An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations. *Clinical and Applied Thrombosis/Hemostasis*. 2022; 28: 1076029621105666. doi: 10.1177/10760296211056648

28. Lee P, Kim CU, Seo SH, et al. Current Status of COVID-19 Vaccine Development: Focusing on Antigen Design and Clinical Trials on Later Stages. *Immune Network*. 2021; 21(1). doi: 10.4110/in.2021.21.e4
29. Sharma O, Sultan AA, Ding H, et al. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. *Frontiers in Immunology*. 2020; 11. doi: 10.3389/fimmu.2020.585354
30. Evans JP, Liu SL. Role of host factors in SARS-CoV-2 entry. *Journal of Biological Chemistry*. 2021; 297(1): 100847. doi: 10.1016/j.jbc.2021.100847
31. Milewska A, Zarebski M, Nowak P, et al. Human Coronavirus NL63 Utilizes Heparan Sulfate Proteoglycans for Attachment to Target Cells. *Journal of Virology*. 2014; 88(22): 13221-13230. doi: 10.1128/jvi.02078-14
32. Lang J, Yang N, Deng J, et al. Inhibition of SARS Pseudovirus Cell Entry by Lactoferrin Binding to Heparan Sulfate Proteoglycans. *PLoS ONE*. 2011; 6(8): e23710. doi: 10.1371/journal.pone.0023710
33. Vlasak R, Luytjes W, Spaan W, et al. Human and bovine coronaviruses recognize sialic acid-containing receptors similar to those of influenza C viruses. *Proceedings of the National Academy of Sciences*. 1988; 85(12): 4526-4529. doi: 10.1073/pnas.85.12.4526
34. Chan CM, Chu H, Wang Y, et al. Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 Is an Important Surface Attachment Factor That Facilitates Entry of Middle East Respiratory Syndrome Coronavirus. *Journal of Virology*. 2016; 90(20): 9114-9127. doi: 10.1128/jvi.01133-16
35. Yeager CL, Ashmun RA, Williams RK, et al. Human aminopeptidase N is a receptor for human coronavirus 229E. *Nature*. 1992; 357(6377): 420-422. doi: 10.1038/357420a0
36. Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. *Nature*. 2013; 495(7440): 251-254. doi: 10.1038/nature12005
37. Collins AR. HLA Class I Antigen Serves as a Receptor for Human Coronavirus OC43. *Immunological Investigations*. 1993; 22(2): 95-103. doi: 10.3109/08820139309063393
38. Cantuti-Castelvetri L, Ojha R, Pedro LD, et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. *Science*. 2020; 370(6518): 856-860. doi: 10.1126/science.abd2985
39. Daly JL, Simonetti B, Klein K, et al. Neuropilin-1 is a host factor for SARS-CoV-2 infection. *Science*. 2020; 370(6518): 861-865. doi: 10.1126/science.abd3072
40. Hulswit RJG, Lang Y, Bakkers MJG, et al. Human coronaviruses OC43 and HKU1 bind to 9- O -acetylated sialic acids via a conserved receptor-binding site in spike protein domain A. *Proceedings of the National Academy of Sciences*. 2019; 116(7): 2681-2690. doi: 10.1073/pnas.1809667116
41. Bestle D, Heindl MR, Limburg H, et al. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. *Life Science Alliance*. 2020; 3(9): e202000786. doi: 10.26508/lsa.202000786
42. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*. 2020; 181(2): 271-280.e8. doi: 10.1016/j.cell.2020.02.052
43. Simmons G, Gosalia DN, Rennekamp AJ, et al. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. *Proceedings of the National Academy of Sciences*. 2005; 102(33): 11876-11881. doi: 10.1073/pnas.0505577102
44. Kawase M, Shirato K, van der Hoek L, et al. Simultaneous Treatment of Human Bronchial Epithelial Cells with Serine and Cysteine Protease Inhibitors Prevents Severe Acute Respiratory Syndrome Coronavirus Entry. *Journal of Virology*. 2012; 86(12): 6537-6545. doi: 10.1128/jvi.00094-12
45. Matsuyama S, Nagata N, Shirato K, et al. Efficient Activation of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein by the Transmembrane Protease TMPRSS2. *Journal of Virology*. 2010; 84(24): 12658-12664. doi: 10.1128/JVI.01542-10
46. Glowacka I, Bertram S, Müller MA, et al. Evidence that TMPRSS2 Activates the Severe Acute Respiratory Syndrome Coronavirus Spike Protein for Membrane Fusion and Reduces Viral Control by the Humoral Immune Response. *Journal of Virology*. 2011; 85(9): 4122-4134. doi: 10.1128/jvi.02232-10
47. Shulla A, Heald-Sargent T, Subramanya G, et al. A Transmembrane Serine Protease Is Linked to the Severe Acute Respiratory Syndrome Coronavirus Receptor and Activates Virus Entry. *Journal of Virology*. 2011; 85(2): 873-882. doi: 10.1128/jvi.02062-10
48. Sungnak W, Huang N, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. *Nature Medicine*. 2020; 26(5): 681-687. doi: 10.1038/s41591-020-0868-6
49. Milewska A, Falkowski K, Kalinska M, et al. Kallikrein 13: a new player in coronaviral infections. Published online March 2, 2020. doi: 10.1101/2020.03.01.971499
50. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*. 2020; 395(10229): 1054-1062.
51. Essalmani R, Jain J, Susan-Resiga D, et al. Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity. *Journal of Virology*. 2022; 96(8). doi: 10.1128/jvi.00128-22

52. Ragotte RJ, Pulido D, Donnellan FR, et al. Human Basigin (CD147) Does Not Directly Interact with SARS-CoV-2 Spike Glycoprotein. *mSphere*. 2021; 6(4). doi: 10.1128/msphere.00647-21
53. Shilts J, Crozier TWM, Greenwood EJD, et al. No evidence for basigin/CD147 as a direct SARS-CoV-2 spike binding receptor. *Scientific Reports*. 2021; 11(1). doi: 10.1038/s41598-020-80464-1
54. Johnson BA, Xie X, Bailey AL, et al. Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis. *Nature*. 2021; 591(7849): 293-299. doi: 10.1038/s41586-021-03237-4
55. Liu C, von Brunn A, Zhu D. Cyclophilin A and CD147: novel therapeutic targets for the treatment of COVID-19. *Medicine in Drug Discovery*. 2020; 7: 100056. doi: 10.1016/j.medidd.2020.100056
56. Rahimi N. C-Type Lectin CD209L/L-SIGN and CD209/DC-SIGN: Cell Adhesion Molecules Turned to Pathogen Recognition Receptors. Published online November 9, 2020. doi: 10.20944/preprints202011.0245.v2
57. Guo L, Liang Y, Li H, et al. Epigenetic glycosylation of SARS-CoV-2 impact viral infection through DC&L-SIGN receptors. *iScience*. 2021; 24(12): 103426. doi: 10.1016/j.isci.2021.103426
58. Amraei R, Yin W, Napoleon MA, et al. CD209L/L-SIGN and CD209/DC-SIGN act as receptors for SARS-CoV-2. Published online June 23, 2020. doi: 10.1101/2020.06.22.165803
59. Thépaut M, Luczkowiak J, Vivès C, et al. DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist. Published online August 10, 2020. doi: 10.1101/2020.08.09.242917
60. Lempp FA, Soriaga LB, Montiel-Ruiz M, et al. Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies. *Nature*. 2021; 598(7880): 342-347. doi: 10.1038/s41586-021-03925-1
61. Sewald X, Ladinsky MS, Uchil PD, et al. Retroviruses use CD169-mediated trans-infection of permissive lymphocytes to establish infection. *Science*. 2015; 350(6260): 563-567. doi: 10.1126/science.aab2749
62. Kondo Y, Larabee JL, Gao L, et al. L-SIGN is a receptor on liver sinusoidal endothelial cells for SARS-CoV-2 virus. *JCI Insight*. 2021; 6(14). doi: 10.1172/jci.insight.148999
63. Ali YM, Ferrari M, Lynch NJ, et al. Lectin Pathway Mediates Complement Activation by SARS-CoV-2 Proteins. *Frontiers in Immunology*. 2021; 12. doi: 10.3389/fimmu.2021.714511
64. Anthony R. Faculty Opinions recommendation of SARS-CoV-2 exacerbates proinflammatory responses in myeloid cells through C-type lectin receptors and Tweety family member 2. Faculty Opinions—Post-Publication Peer Review of the Biomedical Literature; 2012.
65. Vora SM, Lieberman J, Wu H. Inflammasome activation at the crux of severe COVID-19. *Nature Reviews Immunology*. 2021; 21(11): 694-703. doi: 10.1038/s41577-021-00588-x
66. Soker S, Takashima S, Miao HQ, et al. Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor. *Cell*. 1998; 92(6): 735-745.
67. Kyrou I, Randeva HS, Spandidos DA, et al. Not only ACE2—the quest for additional host cell mediators of SARS-CoV-2 infection: Neuropilin-1 (NRP1) as a novel SARS-CoV-2 host cell entry mediator implicated in COVID-19. *Signal Transduction and Targeted Therapy*. 2021; 6(1). doi: 10.1038/s41392-020-00460-9
68. Gu Y, Cao J, Zhang X, et al. Receptome profiling identifies KREMEN1 and ASGR1 as alternative functional receptors of SARS-CoV-2. *Cell Research*. 2021; 32(1): 24-37. doi: 10.1038/s41422-021-00595-6
69. Hoffmann M, Pöhlmann S. Novel SARS-CoV-2 receptors: ASGR1 and KREMEN1. *Cell Research*. 2021; 32(1): 1-2. doi: 10.1038/s41422-021-00603-9
70. Staring J, van den Hengel LG, Raaben M, et al. KREMEN1 Is a Host Entry Receptor for a Major Group of Enteroviruses. *Cell Host & Microbe*. 2018; 23(5): 636-643.e5. doi: 10.1016/j.chom.2018.03.019
71. Zhao Y, Zhou D, Ni T, et al. Hand-foot-and-mouth disease virus receptor KREMEN1 binds the canyon of Coxsackie Virus A10. *Nature Communications*. 2020; 11(1). doi: 10.1038/s41467-019-13936-2
72. Lv J, Wang Z, Qu Y, et al. Distinct uptake, amplification, and release of SARS-CoV-2 by M1 and M2 alveolar macrophages. *Cell Discovery*. 2021; 7(1). doi: 10.1038/s41421-021-00258-1
73. Abassi Z, Knaney Y, Karraam T, et al. The Lung Macrophage in SARS-CoV-2 Infection: A Friend or a Foe? *Frontiers in Immunology*. 2020; 11. doi: 10.3389/fimmu.2020.01312
74. Gracia-Hernandez M, Sotomayor EM, Villagra A. Targeting Macrophages as a Therapeutic Option in Coronavirus Disease 2019. *Frontiers in Pharmacology*. 2020; 11. doi: 10.3389/fphar.2020.577571
75. Parkos C, Brazil J. Faculty Opinions recommendation of Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature. Faculty Opinions Ltd; 2021.
76. Sefik E, Qu R, Junqueira C, et al. Inflammasome activation in infected macrophages drives COVID-19 pathology. Cold Spring Harbor Laboratory; 2021.
77. Bost P, Giladi A, Liu Y, et al. Host-Viral Infection Maps Reveal Signatures of Severe COVID-19 Patients. *Cell*. 2020; 181(7): 1475-1488.e12. doi: 10.1016/j.cell.2020.05.006
78. Chen ST, Park MD, Del Valle DM, et al. Shift of lung macrophage composition is associated with COVID-19 disease severity and recovery. Cold Spring Harbor Laboratory; 2022.

79. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. *Journal of Clinical Investigation*. 2012; 122(3): 787-795. doi: 10.1172/jci59643
80. Junqueira C, Crespo Â, Ranjbar S, et al. FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation. *Nature*. 2022; 606(7914): 576-584. doi: 10.1038/s41586-022-04702-4
81. Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. *Nature Reviews Immunology*. 2020; 20(6): 355-362. doi: 10.1038/s41577-020-0331-4
82. Bräutigam K, Reinhard S, Galván JA, et al. Systematic Investigation of SARS-CoV-2 Receptor Protein Distribution along Viral Entry Routes in Humans. *Respiration*. 2022; 101(6): 610-618. doi: 10.1159/000521317
83. Bräutigam K, Reinhard S, Wartenberg M, et al. Comprehensive analysis of SARS - CoV - 2 receptor proteins in human respiratory tissues identifies alveolar macrophages as potential virus entry site. *Histopathology*. 2023; 82(6): 846-859. doi: 10.1111/his.14871
84. Zou X, Chen K, Zou J, et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. *Frontiers of Medicine*. 2020; 14(2): 185-192. doi: 10.1007/s11684-020-0754-0
85. Synowiec A, Szczepański A, Barreto-Duran E, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): a Systemic Infection. *Clinical Microbiology Reviews*. 2021; 34(2). doi: 10.1128/cmr.00133-20
86. Oran DP, Topol EJ. The Proportion of SARS-CoV-2 Infections That Are Asymptomatic. *Annals of Internal Medicine*. 2021; 174(5): 655-662.
87. Gao Z, Xu Y, Sun C, et al. A systematic review of asymptomatic infections with COVID-19. *Journal of Microbiology, Immunology and Infection*. 2021; 54(1): 12-16. doi: 10.1016/j.jmii.2020.05.001
88. Markov PV, Katzourakis A, Stilianakis NI. Antigenic evolution will lead to new SARS-CoV-2 variants with unpredictable severity. *Nature Reviews Microbiology*. 2022; 20(5): 251-252. doi: 10.1038/s41579-022-00722-z
89. Murray CJL, Piot P. The Potential Future of the COVID-19 Pandemic. *JAMA*. 2021; 325(13): 1249. doi: 10.1001/jama.2021.2828
90. Kayser V, Ramzan I. Vaccines and vaccination: history and emerging issues. *Human Vaccines & Immunotherapeutics*. 2021; 17(12): 5255-5268. doi: 10.1080/21645515.2021.1977057
91. Colson P, Fournier PE, Delerce J, et al. Culture and identification of a “Deltamircron” SARS-CoV-2 in a three cases cluster in southern France. *Cold Spring Harbor Laboratory*; 2022.
92. Luring AS, Hodcroft EB. Genetic Variants of SARS-CoV-2—What Do They Mean? *JAMA*. 2021; 325(6): 529. doi: 10.1001/jama.2020.27124
93. Hossain A, Akter S, Rashid AA, et al. Unique mutations in SARS-CoV-2 Omicron subvariants’ non-spike proteins: Potential impacts on viral pathogenesis and host immune evasion. *Microbial Pathogenesis*. 2022; 170: 105699. doi: 10.1016/j.micpath.2022.105699
94. Wu L, Zhou L, Mo M, et al. SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2. *Signal Transduction and Targeted Therapy*. 2022; 7(1). doi: 10.1038/s41392-021-00863-2
95. Chen TH, Hsu MT, Lee MY, et al. Gastrointestinal Involvement in SARS-CoV-2 Infection. *Viruses*. 2022; 14(6): 1188. doi: 10.3390/v14061188
96. Plummer JT, Contreras D, Zhang W, et al. US Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Epsilon Variant: Highly Transmissible but With an Adjusted Muted Host T-Cell Response. *Clin Infect Dis*; 2022.
97. Callaway E. COVID vaccine boosters: the most important questions. *Nature*. 2021; 596(7871): 178-180. doi: 10.1038/d41586-021-02158-6
98. Klocke RA. *Respiration human*, Encyclopædia Britannica Student and Home Edition. Encyclopædia Britannica; 2013.
99. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. *New England Journal of Medicine*. 2020; 382(13): 1199-1207. doi: 10.1056/nejmoa2001316
100. Riou J, Althaus CL. Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. *Eurosurveillance*. 2020; 25(4). doi: 10.2807/1560-7917.es.2020.25.4.2000058
101. Wu CT, Lidsky PV, Xiao Y, et al. SARS-CoV-2 replication in airway epithelia requires motile cilia and microvillar reprogramming. *Cell*. 2023; 186(1): 112-130.e20. doi: 10.1016/j.cell.2022.11.030
102. Owen J, Punt J, Stranford S. *KUBY Immunology*, 7th ed. Freeman and Company; 2023.
103. Liu G, Lee JH, Parker ZM, et al. ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-CoV-2 papain-like protease to evade host innate immunity. *Nature Microbiology*. 2021; 6(4): 467-478. doi: 10.1038/s41564-021-00884-1

104. WHO. COVID-19 vaccine tracker and landscape. Available online: <https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidatevaccines> (accessed on 2 January 2024).
105. Liu C, Martins AJ, Lau WW, et al. Time-resolved systems immunology reveals a late juncture linked to fatal COVID-19. *Cell*. 2021; 184(7): 1836-1857.e22. doi: 10.1016/j.cell.2021.02.018
106. Wurfel MM, Gordon AC, Holden TD, et al. Toll-like Receptor 1 Polymorphisms Affect Innate Immune Responses and Outcomes in Sepsis. *American Journal of Respiratory and Critical Care Medicine*. 2008; 178(7): 710-720. doi: 10.1164/rccm.200803-462oc
107. Tisoncik JR, Korth MJ, Simmons CP, et al. Into the Eye of the Cytokine Storm. *Microbiology and Molecular Biology Reviews*. 2012; 76(1): 16-32. doi: 10.1128/mmbr.05015-11
108. Song P, Li W, Xie J, et al. Cytokine storm induced by SARS-CoV-2. *Clinica Chimica Acta*. 2020; 509: 280-287. doi: 10.1016/j.cca.2020.06.017
109. Ragab D, Salah Eldin H, Taeimah M, et al. The COVID-19 Cytokine Storm; What We Know So Far. *Frontiers in Immunology*. 2020; 11. doi: 10.3389/fimmu.2020.01446
110. Li F, Li J, Wang PH, et al. SARS-CoV-2 spike promotes inflammation and apoptosis through autophagy by ROS-suppressed PI3K/AKT/mTOR signaling. *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease*. 2021; 1867(12): 166260. doi: 10.1016/j.bbdis.2021.166260
111. Wang M, Chang W, Zhang L, et al. Pyroptotic cell death in SARS-CoV-2 infection: revealing its roles during the immunopathogenesis of COVID-19. *International Journal of Biological Sciences*. 2022; 18(15): 5827-5848. doi: 10.7150/ijbs.77561
112. Rabiou Abubakar A, Ahmad R, Rowaiye AB, et al. Targeting Specific Checkpoints in the Management of SARS-CoV-2 Induced Cytokine Storm. *Life*. 2022; 12(4): 478. doi: 10.3390/life12040478
113. Ghosh S, Das S, et al. A review on the eddect of COVID-19 in type 2 asthma and its management. *Int Immunopharmacol*. 2021; 91: 107309.
114. Massey BW, Jayathilake K, Meltzer HY. Respiratory Microbial Co-infection With SARS-CoV-2. *Frontiers in Microbiology*. 2020; 11. doi: 10.3389/fmicb.2020.02079
115. Bengoechea JA, Bamford CG. SARS - CoV - 2, bacterial co - infections, and AMR: the deadly trio in COVID - 19? *EMBO Molecular Medicine*. 2020; 12(7). doi: 10.15252/emmm.202012560
116. Boutin S, Hildebrand D, Boulant S, et al. Host factors facilitating SARS - CoV - 2 virus infection and replication in the lungs. *Cellular and Molecular Life Sciences*. 2021; 78(16): 5953-5976. doi: 10.1007/s00018-021-03889-5
117. Ma L, Wang W, Le Grange JM, et al. Coinfection of SARS-CoV-2 and Other Respiratory Pathogens. *Infection and Drug Resistance*. 2020; 13: 3045-3053.
118. Mirzaei R, Goodarzi P, Asadi M, et al. Bacterial co - infections with SARS - CoV - 2. *IUBMB Life*. 2020; 72(10): 2097-2111. doi: 10.1002/iub.2356
119. Rhoades NS, Pinski AN, Monsibais AN, et al. Acute SARS-CoV-2 infection is associated with an increased abundance of bacterial pathogens, including *Pseudomonas aeruginosa* in the nose. *Cell Reports*. 2021; 36(9): 109637. doi: 10.1016/j.celrep.2021.109637
120. Qu J, Cai Z, Duan X, et al. *Pseudomonas aeruginosa* modulates alginate biosynthesis and type VI secretion system in two critically ill COVID-19 patients. *Cell & Bioscience*. 2022; 12(1). doi: 10.1186/s13578-022-00748-z
121. Fage C, Hénaut M, Carbonneau J, et al. Influenza A(H1N1)pdm09 Virus but Not Respiratory Syncytial Virus Interferes with SARS-CoV-2 Replication during Sequential Infections in Human Nasal Epithelial Cells. *Viruses*. 2022; 14(2): 395. doi: 10.3390/v14020395
122. Majchrzak M, Poręba M. The roles of cellular protease interactions in viral infections and programmed cell death: a lesson learned from the SARS-CoV-2 outbreak and COVID-19 pandemic. *Pharmacological Reports*. 2022; 74(6): 1149-1165.
123. Tojo K, Yamamoto N, Tamada N, et al. Early alveolar epithelial cell necrosis is a potential driver of COVID-19-induced acute respiratory distress syndrome. *iScience*. 2023; 26(1): 105748. doi: 10.1016/j.isci.2022.105748
124. Yang J, Wang W, Chen Z, et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. *Nature*. 2020; 586(7830): 572-577. doi: 10.1038/s41586-020-2599-8
125. Paolini A, Borella R, De Biasi S, et al. Cell Death in Coronavirus Infections: Uncovering Its Role during COVID-19. *Cells*. 2021; 10(7): 1585.
126. Ramlall V, Thangaraj PM, Meydan C, et al. Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection. *Nature Medicine*. 2020; 26(10): 1609-1615. doi: 10.1038/s41591-020-1021-2
127. Lopez J, Mommert M, Mouton W, et al. Correction: Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs. *Journal of Experimental Medicine*.

- 2021; 218(10). doi: 10.1084/jem.2021121108132021c
128. Diamond MS, Lambris JD, Ting JP, et al. Considering innate immune responses in SARS-CoV-2 infection and COVID-19. *Nature Reviews Immunology*. 2022; 22(8): 465-470. doi: 10.1038/s41577-022-00744-x
129. Chauvineau-Grenier A, Bastard P, Servajean A, et al. Autoantibodies neutralizing type I interferons in 20% of COVID-19 deaths in a French hospital. *Research Square Platform LLC*; 2021.
130. García JT, Bastard P, Planas-Serra L, et al. Neutralizing autoantibodies to type I IFNs in > 10% of patients with severe COVID-19 pneumonia hospitalized in Madrid, Spain. *Research Square Platform LLC*; 2021.
131. Wilk AJ, Rustagi A, Zhao NQ, et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. *Nature Medicine*. 2020; 26(7): 1070-1076. doi: 10.1038/s41591-020-0944-y
132. Wilk AJ, Lee MJ, Wei B, et al. Multi-omic profiling reveals widespread dysregulation of innate immunity and hematopoiesis in COVID-19. *Journal of Experimental Medicine*. 2021; 218(8). doi: 10.1084/jem.20210582
133. Wong LYR, Zheng J, Wilhelmssen K, et al. Eicosanoid signalling blockade protects middle-aged mice from severe COVID-19. *Nature*. 2022; 605(7908): 146-151. doi: 10.1038/s41586-022-04630-3
134. Biondo C, Midiri A, Gerace E, et al. SARS-CoV-2 Infection in Patients with Cystic Fibrosis: What We Know So Far. *Life*. 2022; 12(12): 2087. doi: 10.3390/life12122087
135. Selva KJ, Chung AW. Insights into how SARS-CoV2 infection induces cytokine storms. *Trends in Immunology*. 2022; 43(6): 417-419. doi: 10.1016/j.it.2022.04.007
136. Scully EP, Haverfield J, Ursin RL, et al. Considering how biological sex impacts immune responses and COVID-19 outcomes. *Nature Reviews Immunology*. 2020; 20(7): 442-447. doi: 10.1038/s41577-020-0348-8
137. Mallapaty S. The coronavirus is most deadly if you are older and male—new data reveal the risks. *Nature*. 2020; 585(7823): 16-17.
138. Akbar AN, Gilroy DW. Aging immunity may exacerbate COVID-19. *Science*. 2020; 369(6501): 256-257. doi: 10.1126/science.abb0762
139. Saifi S, Ravi V, Sharma S, et al. SARS-CoV-2 VOCs, Mutational diversity and clinical outcome: Are they modulating drug efficacy by altered binding strength? *Genomics*. 2022; 114(5): 110466. doi: 10.1016/j.ygeno.2022.110466
140. Thye AYK, Law JWF, Pusparajah P, et al. Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis. *Biomedicines*. 2021; 9(10): 1303. doi: 10.3390/biomedicines9101303
141. Tosta S, Moreno K, Schuab G, et al. Global SARS-CoV-2 genomic surveillance: What we have learned (so far). *Infection, Genetics and Evolution*. 2023; 108: 105405. doi: 10.1016/j.meegid.2023.105405
142. The-White-House. Fact Sheet: Biden Administration Announces \$1.7 Billion Investment to Fight COVID-19 Variants. The White House; 2021.
143. Hoang T, da Silva AG, Jennison AV, et al. AusTrakka: Fast-tracking nationalized genomics surveillance in response to the COVID-19 pandemic. *Nature Communications*. 2022; 13(1). doi: 10.1038/s41467-022-28529-9
144. Tegally H, San JE, Cotten M, et al. The evolving SARS-CoV-2 epidemic in Africa: insights from rapidly expanding genomic surveillance. *Science*. 2022; 378: 6615.
145. Santiago GA, Flores B, González GL, et al. Genomic surveillance of SARS-CoV-2 in Puerto Rico enabled early detection and tracking of variants. *Communications Medicine*. 2022; 2(1). doi: 10.1038/s43856-022-00168-7
146. Grimaldi A, Panariello F, Annunziata P, et al. Improved SARS-CoV-2 sequencing surveillance allows the identification of new variants and signatures in infected patients. *Genome Medicine*. 2022; 14(1). doi: 10.1186/s13073-022-01098-8
147. Geidelberg L, Boyd O, Jorgensen D, et al. Genomic epidemiology of a densely sampled COVID-19 outbreak in China. Cold Spring Harbor Laboratory; 2020.
148. Stockdale JE, Liu P, Colijn C. The potential of genomics for infectious disease forecasting. *Nature Microbiology*. 2022; 7(11): 1736-1743. doi: 10.1038/s41564-022-01233-6
149. CDC. CDC's Role in Tracking Variants. Available online: <https://www.cdc.gov/coronavirus/2019-ncov/variants/cdc-role-surveillance.html> (accessed on 2 January 2024).
150. Ellingford JM, George R, McDermott JH, et al. Genomic and healthcare dynamics of nosocomial SARS-CoV-2 transmission. *eLife*; 2021.
151. Houwaart T, Belhaj S, Tawalbeh E, et al. Integrated genomic surveillance enables tracing of person-to-person SARS-CoV-2 transmission chains during community transmission and reveals extensive onward transmission of travel-imported infections, Germany, June to July 2021. *Eurosurveillance*. 2022; 27(43). doi: 10.2807/1560-7917.es.2022.27.43.2101089
152. ECDC. European Centre for Disease Prevention and Control. Guidance for representative and targeted genomic SARS-CoV-2 monitoring—3 May 2021. ECDC; 2021.
153. Bhat S, Pandey A, Kanakan A, et al. Learning from Biological and Computational Machines: Importance of

- SARS-CoV-2 Genomic Surveillance, Mutations and Risk Stratification. *Frontiers in Cellular and Infection Microbiology*. 2021; 11. doi: 10.3389/fcimb.2021.783961
154. Robishaw JD, Alter SM, Solano JJ, et al. Genomic surveillance to combat COVID-19: challenges and opportunities. *The Lancet Microbe*. 2021; 2(9): e481-e484.
155. Carabelli AM, Peacock TP, Thorne LG, et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. *Nature Reviews Microbiology*; 2023.
156. Ling-Hu T, Rios-Guzman E, Lorenzo-Redondo R, et al. Challenges and Opportunities for Global Genomic Surveillance Strategies in the COVID-19 Era. *Viruses*. 2022; 14(11): 2532. doi: 10.3390/v14112532
157. Jiang M, Zhang G, Liu H, et al. Epitope Profiling Reveals the Critical Antigenic Determinants in SARS-CoV-2 RBD-Based Antigen. *Frontiers in Immunology*. 2021; 12. doi: 10.3389/fimmu.2021.707977
158. Abd El-Baky N, Amara AAAF. Depending on Epitope Profile of COVID-19 mRNA Vaccine Recipients: Are They More Efficient Against the Arising Viral Variants? An Opinion Article. *Frontiers in Medicine*. 2022; 9. doi: 10.3389/fmed.2022.903876
159. Abd El-Baky N, Amara A, Redwan E. HLA-I and HLA-II Peptidomes of SARS-CoV-2: A Review. *Vaccines*. 2023; 11(3): 548. doi: 10.3390/vaccines11030548
160. Croft NP, Smith SA, Pickering J, et al. Most viral peptides displayed by class I MHC on infected cells are immunogenic. *Proceedings of the National Academy of Sciences*. 2019; 116(8): 3112-3117. doi: 10.1073/pnas.1815239116
161. Yerly D, Heckerman D, Allen TM, et al. Increased Cytotoxic T-Lymphocyte Epitope Variant Cross-Recognition and Functional Avidity Are Associated with Hepatitis C Virus Clearance. *Journal of Virology*. 2008; 82(6): 3147-3153. doi: 10.1128/jvi.02252-07
162. Hensen L, Illing PT, Rowntree LC, et al. T Cell Epitope Discovery in the Context of Distinct and Unique Indigenous HLA Profiles. *Frontiers in Immunology*. 2022; 13. doi: 10.3389/fimmu.2022.812393
163. Campbell KM, Steiner G, Wells DK, et al. Prioritization of SARS-CoV-2 epitopes using a pan-HLA and global population inference approach. Published online April 1, 2020. doi: 10.1101/2020.03.30.016931
164. Grifoni A, Sidney J, Zhang Y, et al. A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2. *Cell Host & Microbe*. 2020; 27(4): 671-680.e2. doi: 10.1016/j.chom.2020.03.002
165. Joshi A, Joshi BC, Mannan MA ul, et al. Epitope based vaccine prediction for SARS-COV-2 by deploying immuno-informatics approach. *Informatics in Medicine Unlocked*. 2020; 19: 100338. doi: 10.1016/j.imu.2020.100338
166. Kiyotani K, Toyoshima Y, Nemoto K, et al. Bioinformatic prediction of potential T cell epitopes for SARS-Cov-2. *Journal of Human Genetics*. 2020; 65(7): 569-575. doi: 10.1038/s10038-020-0771-5
167. Nelde A, Bilich T, Heitmann JS, et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. *Nature Immunology*. 2020; 22(1): 74-85. doi: 10.1038/s41590-020-00808-x
168. Lin L, Ting S, Yufei H, et al. Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2. *Virus Research*. 2020; 288: 198082. doi: 10.1016/j.virusres.2020.198082
169. Poran A, Harjanto D, Malloy M, et al. Sequence-based prediction of SARS-CoV-2 vaccine targets using a mass spectrometry-based bioinformatics predictor identifies immunogenic T cell epitopes. *Genome Medicine*. 2020; 12(1). doi: 10.1186/s13073-020-00767-w
170. Zhang F, Gan R, Zhen Z, et al. Adaptive immune responses to SARS-CoV-2 infection in severe versus mild individuals. *Signal Transduction and Targeted Therapy*. 2020; 5(1). doi: 10.1038/s41392-020-00263-y
171. Sekine T, Perez-Potti A, Rivera-Ballesteros O, et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. *Cell*. 2020; 183(1): 158-168.